Liquid formulation of Vimpat relaunched

The antiepileptic Vimpat (lacosamide) has been relaunched by UCB Pharma and is now formulated as a lower strength syrup.

Vimpat syrup is unsuitable for patients with phenylketonuria
Vimpat syrup is unsuitable for patients with phenylketonuria

Vimpat (lacosamide) 10mg/ml syrup is indicated for the adjunctive treatment of partial onset-seizures with or without secondary generalisation in adults and children 16 years of age and older. The 10mg/ml syrup replaces the previous 15mg/ml formulation, which was recalled in 2011.

View Vimpat Syrup drug record

Further information: UCB Pharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases